Compugen (CGEN) Q3 2024 earnings summary

Executive summary

• Presented encouraging and durable clinical data for COM701 combinations in platinum-resistant ovarian cancer, confirming activity and safety in over 40 heavily pretreated patients, with good tolerability and durable responses even in populations with low immunotherapy response rates.

• Outlined a new development path for COM701 as maintenance therapy in relapsed platinum-sensitive ovarian cancer, targeting an unmet need with less competition.

• Announced plans for an adaptive platform trial for COM701 in Q2 2025, starting with a randomized, double-blind sub-study of monotherapy versus placebo, with future combination arms possible.

• Partner AstraZeneca advanced rilvegostomig (derived from COM902) into multiple Phase 3 lung cancer trials, with promising efficacy and safety data presented at WCLC and ESMO 2024.

• Cash runway expected to fund operations into 2027, with no debt and significant milestone revenue from partnerships.

Financial highlights

• Cash, cash equivalents, and investments totaled $113.2 million as of September 30, 2024, up from $51.1 million at year-end 2023, including a $30 million milestone payment for COM503.

• Q3 2024 revenues were $17.1 million, reflecting recognition of upfront and milestone payments from Gilead for COM503.

• R&D expenses for Q3 2024 were $6.3 million, down from $8.3 million in Q3 2023, mainly due to reclassification and lower COM503 costs.

• Net profit for Q3 2024 was $1.3 million (one cent per share), compared to a net loss of $9.9 million (11 cents per share) in Q3 2023.

• Gross profit for Q3 2024 was $13.5 million; operating profit was $4.5 million.

Outlook and guidance

• Planned initiation of the COM701 maintenance trial in platinum-sensitive ovarian cancer in Q2 2025, with interim analysis data expected in H2 2026.

• Platform trial design allows for future expansion into combination therapies and biomarker-enriched sub-studies.

• Q4 2024: Initiate Phase 1 study of COM503 in solid tumors.

• Cash runway projected to last into 2027, supporting key clinical milestones and pipeline advancement.